|
| Home : FDA Alert on Controversial MS Therapy |
|
May 11
2012 |
FDA Alert on Controversial MS Therapy |
|
The U.S. Food and Drug Administration issued a warning about the potential risks of an experimental therapy used to treat a condition -- chronic cerebrospinal venous insufficiency, or CCSVI -- often linked to multiple sclerosis.
|
|
|
|
| Source:http://feeds.abcnews.com/click.phdo?i=e0cfdf80e916c4139a6ce8dbd724f857 |
| |
|
Related News
|
» FDIC: End 'Too Big to Fail' Bailouts
» JPMorgan Announces Surprise $2B Loss
|
|
|
